Programmed death ligand 1 (PDL-1) expression in triple negative breast cancer cells: New proposal for a "tumor score" definition

Research output: Contribution to journalArticlepeer-review

Abstract

Recently, several studies showed that PDL-1 pathway may have a key role in the interaction of tumor cells with host immune response, and PDL-1 expression of tumor cells may serve as a mechanism of adaptive immune resistance. The data available in the literature about PDL-1 immunohistochemical expression in tumor tissues are not uniform, for the use of different antibodies clones and the absence of a standardized operative protocol. In this study we analyzed PDL-1 expression in a series of triple negative breast cancers and defined a standardized protocol suggesting a "tumor score" for its evaluation. Its application on large tumor case series will allow to investigate the real prognostic value of PD-L1.

Original languageEnglish
Pages (from-to)11693-11696
Number of pages4
JournalInternational Journal of Clinical and Experimental Pathology
Volume9
Issue number11
Publication statusPublished - 2016

Keywords

  • PD-L1
  • TNBC
  • Tumor score

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology

Fingerprint Dive into the research topics of 'Programmed death ligand 1 (PDL-1) expression in triple negative breast cancer cells: New proposal for a "tumor score" definition'. Together they form a unique fingerprint.

Cite this